Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

Karina found her fit at Lilly through our summer internship program. She is now hoping to inspire more Latinx students to make changes in the STEM field just as her mentor did for her. Visit careers.lilly.com/LRL to find open roles in Lilly’s research labs. #WeAreLilly

893 S Delaware St
Indianapolis, IN 46285

Discovery is
in our DNA

Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.

Explore Careers

We are Lilly

Why do our employees love coming to work each and every day? Here’s what they have to say.

“Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”

Kavita - Associate Director, Packaging Operations
“Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”

Adrian - Associate Director, IDM
“What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”

Cecile - Sr Director, Design Hub Foundations

39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.

View Stories

NEWS

Pharmaceutical research and new medicine biotechnology or revolutionary medication discovery health concept with prescription pill symbols with 3D illustration elements.

Obesity

Obesity in Focus: ADA Reveals R&D Priorities for Blockbusters-in-Waiting

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next generation of weight loss medicines: muscle preservation, limited side effects and novel targets.

July 14, 2025

9 min read

Tristan Manalac

Person buried in paperwork hand raised collage art. Man drown in work concept. Overwork illustration for news banner, web articles, and posters

FDA

FDA Rejections: We Read 200 CRLs So You Don’t Have To

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli Lilly’s Alzheimer’s antibody Kisunla, Sarepta’s DMD gene therapy Vyondys 53 and Gilead’s HIV drug Sunlenca.

July 11, 2025

5 min read

Annalee Armstrong

Human brain with abstract visualization of neuron activity

Alzheimer’s disease

Lilly Gets FDA Label Update for Alzheimer’s Drug To Mitigate Safety Concerns

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of the monoclonal antibody drug class that has led to several deaths.

July 9, 2025

2 min read

Annalee Armstrong

Podcast

Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More

H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health Secretary Robert F. Kennedy Jr. and a plea from patients with ALS for access to BrainStorm’s NurOwn.

July 9, 2025

1 min read

Heather McKenzie

Business vision and target. Businessman holding telescope standing on arrow up go to success in career. Concept business, Achievement, Character, Leader, Vector illustration flat

Drug Development

5 Second-Half Biopharma Milestones To Watch

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in 2025, according to Jefferies.

July 7, 2025

8 min read

Tristan Manalac

Pictured: Office building science collage

Career Advice

The Top 12 Companies Hiring in Biopharma Now

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

July 3, 2025

1 min read

Angela Gabriel

Medical characters fighting the epidemic flat vector concept operation hand drawn illustration

Obesity

Analysts Home In on Safety as Novo, Lilly, Amgen Highlight Weight Loss Data at ADA

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts parsing the data presented at the American Diabetes Association annual meeting this week.

June 27, 2025

5 min read

Heather McKenzie

Successful businessman standing in front of multiple pathways, making a decision for the right move. A symbol of great investment and positive progress in the development of business. stock illustration

Mergers & acquisitions

Lilly-Verve Proxy Filing Reveals Tumult After Departure of FDA’s Marks

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing than normal” given the regulatory turmoil it revealed.

June 26, 2025

4 min read

Annalee Armstrong

A cannon fires bullets as a banknote. Money flow concept. business vector stock illustration

GLP-1

Prescription Drug Sales Will Hit $1.75T By 2030 Thanks to GLP-1s: Evaluate

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be three times larger than what AbbVie’s blockbuster Humira ever achieved.

June 25, 2025

3 min read

Annalee Armstrong

JOBS